# Clinical Features of Urachal Carcinoma in Japan: Review of 157 Patients

M. Ghazizadeh, S. Yamamoto and K. Kurokawa

Department of Urology, School of Medicine, University of Tokushima, Japan

Accepted: March 23, 1983

Summary. Carcinoma of the urachus is not as uncommon as previously considered. 157 cases diagnosed to have urachal carcinoma collected from the Japanese literature were reviewed and the findings were compared with those reported in the English literature. The incidence of the disease ranges from 0.55 to 1.2% of bladder tumours in Japan in contrast with 0.07 to 0.70% in the Western countries. Males accounted for 72% of the patients. The highest age incidence occurred between fifth and sixth decades. The commonest presenting symptom was haematuria (71%). Adenocarcinoma accounted for 88% of the tumours most being mucous producing. Various treatment modalities were used, however, and the prognosis remained uniformly poor. An analysis of 66 patients with known outcome revealed an overall 5-year survival rate of 6%. The authors conclude that the disease tends to have a relatively higher incidence in Japan (Far East). When comparing the parameters of sex, age, presenting symptom, histopathology, treatment and prognosis, urachal carcinoma appears to have the same characteristics in the Far East as in Western countries.

Key words: Urachal carcinoma, Clinical feature in Japan, Comparison with Western countries.

# Introduction

Carcinoma of the urachus arises from the embryonic rests of glandular cells that remain after the process of urachal involution. The most common malignancy of the urachus is adenocarcinoma. There are, at present, 154 cases of urachal carcinoma reported in the English literature [4, 6, 10, 12–14, 18–20, 23, 25]. We herein review 157 cases of urachal carcinoma collected from the Japanese literature and compare our findings with those reported in the Western countries.




Fig. 1. Sex and age distribution of 155 patients

# Review of the Literature

From 1932 to 1981 (49 years) Japanese literature related to the urachal carcinoma was reviewed. Excluding duplications and ambiguous reports, 157 cases appeared to be fit for this study. Data were collected with reference to the incidence, sex, age, presenting symptom, histopathology, treatment and prognosis. Only 66 patients had sufficient data to permit analysis of survival.

# Sex and Age Incidence

Males accounted for about 72% of the patients, whereas 28% were females; the ratio being 2.6:1. The ages ranged from 19 to 82 years with a mean age of 51.6 years in males and 51.2 years in females. The highest age incidence occurred between the fifth and sixth decades (46.5%). One-forth of the patients (25.8%) were less than 40 years old (Fig. 1). The youngest patient was a 19 year-old female and the oldest an 82 year-old male. The sex and age of two patients are not known.

Table 1. Presenting symptoms of patients

| Symptoms <sup>a</sup>    | No. of patients (%) |  |  |
|--------------------------|---------------------|--|--|
| Haematuria               | 112 (71)            |  |  |
| Suprapubic mass          | 18 (11)             |  |  |
| Dysuria, Frequency       | 16 (10)             |  |  |
| Lower abdominal pain     | 9 ( 6)              |  |  |
| Mucous in urine          | 6 (4)               |  |  |
| Necrotic debris in urine | 2 (1)               |  |  |
| Umbilical discharge      | 1 ( 1)              |  |  |
| Unknown                  | 14 ( 9)             |  |  |

a Some patients had more than one symptom

Table 2. Histopathology of tumours

| No. of patients (%) |  |  |
|---------------------|--|--|
| 138 ( 88)           |  |  |
| 5 ( 3)              |  |  |
| 3 (2)               |  |  |
| 6 (4)               |  |  |
| 5 ( 3)              |  |  |
| 157 (100)           |  |  |
|                     |  |  |

Table 3. Treatment of patients

|                                | No. of patients (%) |  |
|--------------------------------|---------------------|--|
| Partial Cystectomy ± Radiation |                     |  |
| and/or Chemotherapy            | 89 ( 57)            |  |
| En bloc Resection ± Radiation  |                     |  |
| and/or Chemotherapy            | 33 (21)             |  |
| Total Cystectomy ± Radiation   | 8 ( 5)              |  |
| Radiation + Chemotherapy       | 4 ( 2)              |  |
| Radiation                      | 3 ( 2)              |  |
| Chemotherapy                   | 1 ( 1)              |  |
| Unknown                        | 19 ( 12)            |  |
| Total                          | 157 (100)           |  |

Table 4. Crude survival data of 66 patients with adenocarcinoma of the urachus

| Years | No. of patients alive | percentage of patients alive |
|-------|-----------------------|------------------------------|
| 1     | 28                    | 42.4                         |
| 2     | 15                    | 22.7                         |
| 3     | 9                     | 13.6                         |
| 4     | 5                     | 7 <b>.</b> 6                 |
| 5     | 4                     | 6.0                          |
| 6     | 4                     | 6.0                          |
| 7     | 3                     | 4.5                          |
| 8     | 2                     | 3.0                          |
| 9     | 1                     | 1.5                          |
| 10    | 1                     | 1.5                          |

#### Clinical Features

The clinical manifestations of urachal carcinoma frequently resemble those of bladder tumours (Table 1). The most common symptom was haematuria (71%), followed in order of frequency by suprapubic mass (11%), dysuria and frequency (10%) and lower abdominal pain (6%). The presence of mucous material in urine was uncommon. Some patients presented with more than one symptom. The symptomatology is not known in 14 patients.

#### Histopathology

Histological evaluation of the tumours showed that the majority, i.e. 138 (88%), were adenocarcinomas. Of these, 88 (64%) were mucous producing. This status is not known in 26 patients. Other histological varieties of the tumour were noted with less frequency (Table 2).

## Treatment and Prognosis

Various modes of therapy were used in this series of patients (Table 3). Eighty-nine patients were treated by partial cystectomy and 33 patients had en bloc segmental resection. The latter entails removal of the tumour and contiguous bladder wall with transversalis fascia and peritoneum along the urachal tract with or without the umbilicus. Only in 8 patients was more aggressive surgery, the (total cystectomy and urinary diversion) used.

In 29 patients radiation with or without chemotherapy was employed as an adjunct to surgery. The most common chemotherapeutic agent used was 5-fluorouracil. In 19 patients, treatment is not known and the remainder was dealt with by radiation and/or chemotherapy alone. The outcome was known in 66 of the 157 patients, which provided the basis for analysis of survival. The crude survival of these patients is shown in Table 4.

In spite of different treatment trials, the prognosis was uniformly poor. The overall 3- and 5-year survivals were 13.6% and 6.0% respectively. The average survival of the 66 patients was 17 months.

# Discussion

Adenocarcinoma of the bladder can be classified into 3 categories, depending on its origin, as primary, metastatic and urachal adenocarcinomas.

Primary adenocarcinoma of the bladder may occur at any site in the bladder, but is frequently located in the base or lateral walls [16]. It may be caused by irritation of the urothelium associated with infection, trauma and obstruction [1, 22]. Wheeler and Hill [22] suggested the following criteria for diagnosis of this lesion: 1. location in the base or lateral walls of the bladder, 2. presence of cystitis cystica or glandularis and, 3. presence of a transition from non-malignant urothelium to adenocarcinoma.

Metastatic adenocarcinoma of the bladder usually originates from a primary lesion in the colon, prostate or female genital tract.

Urachal adenocarcinoma originates from the epithelial mucosa of the urachal remnant. It is located in the dome or anterior bladder wall. The criteria for the diagnosis of this disease entail [16, 22]: 1. location in the dome or

Table 5. Incidence rates of primary adenocarcinoma and urachal carcinoma as a percentage of all bladder tumours in several populations

| Country                    | Reference          | Source of data                | Total<br>bladder<br>tumors | No. of patients (incidence)             |                      |
|----------------------------|--------------------|-------------------------------|----------------------------|---|----------------------|
|                            |                    |                               |                            | Primary<br>adenocarcinoma               | Urachal<br>carcinoma |
| United States <sup>a</sup> |                    |                               |                            |   |                      |
| Iowa                       | Jacobo et al. [9]  | Bladder Tumor Registry        | 2,628                      | 20 (0.76)                               | 6 (0.23)             |
| Seattle                    | Jones et al. [11]  | Virginia Mason Medical Center | 648                        | 10 (1.54)                               | ••••••               |
| England                    |                    |                               |                            |   |                      |
| Bristol                    | Miller et al. [15] | Bladder Tumor Registry        | 1,437                      | *************************************** | 1 (0.07)             |
| Sheffield                  | Thomas et al. [21] | United Sheffield Hospitals    | 5,300                      | 25 (0.47)                               | 18 (0.34)            |
| Sweden                     | Öhman et al. [18]  | Cancer Registry of Sweden     | 6,000                      | 50 (0.83)                               | 10 (0.17)            |
| West Germany               |                    |                               |                            |   |                      |
| Mainz                      | Jakse et al. [10]  | University of Mainz           | 715                        | 13 (1.8)                                | 5 (0.70)             |
| Hong Kong                  | Yu and Leong [25]  | Queen Mary Hospital           | 290                        | **************                          | 1 (0.34)             |
| Japan                      | Ichikawa [8]       | 38 University Hospitals       | 1,018                      | 40 (3.93)                               | 12 (1.18)            |
| Shikoku                    | Present Study      | Cancer Center                 | 365                        | 6 (1.64)                                | 2 (0.55)             |

<sup>&</sup>lt;sup>a</sup> Also Massachusetts, Cornil et al. [5]: Urachal carcinoma comprises 0.01% of all malignant diseases

anterior wall of the bladder, 2. absence of cystitis cystica and glandularis, 3. presence of a suprapubic mass, 4. invasion into muscular or deeper layers, 5. presence of urachal remnant, 6. sharp demarcation between tumor and surface epithelium, 7. deep ramification into the bladder wall with extension to the space of Retzius, abdominal wall or umbilicus.

A small number of adenocarcinomas of the bladder are of urachal origin. Recent data from the Cancer Center of Shikoku Island in Japan shows that of 365 cases of bladder tumour, there were 6 cases of primary and 2 cases of urachal adenocarcinoma, comprising, respectively, 1.64% and 0.55% of the bladder tumours in this district. In Table 5 the incidence rates of primary adenocarcinoma of the bladder and urachal carcinoma derived from the available literature are summarized. It can be seen that the incidence of urachal carcinoma ranges from 0.07% to 0.70% of the bladder tumours in Western countries in contrast with 0.55% to 1.2% of the bladder tumours in Japan. This reveals that the disease tends to have a relatively higher frequency in Japan than in Western countries.

In our series, 72% of the patients were male subjects which is comparable to the 80% incidence reported in Western literature [23, 17]. The ages ranged from 19 to 82 years old. Cornil et al. [5] reported the youngest patient, a 15 year-old girl, and Bandler et al. [21] the oldest, an 83 year-old male. The highest incidence was between the fifth and sixth decades which corresponds to that reported in Western literature [17, 20]. One-fourth of our cases (25.8%) were less than 40 years old. This is suggestive of an increased frequency of the disease in the younger age group.

Clinical features of urachal carcinoma frequently resemble those of tumours of the bladder, i.e. haematuria, dysuria and frequency (Table 1). In our series 71% of the patients had haematuria. Suprapubic mass, dysuria and frequency and abdominal pain were noted with less frequency. The passage of mucous in the urine has been considered pathognomonic for adenocarcinoma of the urachus [24], but, was observed rarely in this series. Beck et al. [3] reviewing 78 cases of urachal carcinoma from the English literature also found the majority of patients (78%) to have haematuria, while the other symptoms were infrequent. Rubell and Porges [20] reported a case of urachal carcinoma in which the presenting symptom was vaginal bleeding.

Histological distribution of the tumours in our series showed the majority (88%) to be adenocarcinomas mostly of the mucous producing type. This is consistent with that of 80 to 90% reported in Western countries [6]. The diagnosis of urachal carcinoma is usually suspected at cystoscopic examination whenever a lesion at the bladder dome is encountered. Subsequent tumour biopsy may show adenocarcinoma; however, in most cases the site of the tumour origin is established only at operation. Radiographic examination, i.e. IVP and cystogram may show deformity of or a filling defect in the bladder. Ultrasonography and computerized axial tomography have been reported to be worthwhile in the preoperative establishment of the site of the tumour origin in urachal carcinoma [14, 7]. The treatment of urachal carcinoma is always surgery. En bloc removal of the tumour with contiguous bladder wall, transversalis fascia and peritoneum along the urachal tract is reported to be the best choice of treatment with a 5-year survival rate of 25% [23].

In our series various modes of therapy were used (Table 3); however, the prognosis remained uniformly poor. In 66 of the 157 patients, an overall 5-year survival of 6% was obtained (Table 4). Rubell and Porges [20] reviewing

142 cases of urachal carcinoma from the English literature stated that the 5-year survival varied from 6.5% to 16%, but even in the best series only 6% were tumour-free at the end of 5 years.

In conclusion, carcinoma of the urachus appears to have a relatively higher incidence in Japan (Far East) than in Western countries. When comparing the parameters of age, sex, presenting symptom, histopathology, treatment and prognosis, the same characteristics in the Far East were found as in the Western countries.

Acknowledgement. The authors wish to thank Dr. Takeshi Uyama from the Shikoku Cancer Center for kindly supplying the data on incidence of adenocarcinoma of the bladder in Shikoku Island, Japan.

## References

- Abeshouse BS (1943) Extrophy of the bladder complicated by adenocarcinoma of the bladder and renal calculi; a report of a case and a review of the literature. J Urol 49:259-289
- Bandler CG, Roen PR (1950) Mucinous adenocarcinoma arising in urachal cyst and involving bladder. J Urol 64:504
   510
- 3. Beck AD, Gaudin HJ, Bonham DG (1970) Carcinoma of the urachus. Br J Urol 42:555-562
- Cooperman LR (1978) Carcinoma of urachus with extensive abdominal calcification. Urology 12:614-616
- Cornil C, Reynolds CT, Kickham CJE (1967) Carcinoma of the urachus. J Urol 98:93-95
- 6. Ganguli SK (1979) Urachal carcinoma. Urology 13:306-307
- 7. Ghazizadeh M, Yamamoto S, Kurokawa K (1982) CT scan in the diagnosis of urachal carcinoma. Urol Int 37: 358-362
- Ichikawa T (1958) Remote results of the bladder tumors. Jpn J Urol 49:602-610
- Jacobo E, Loening S, Schmidt JD, Culp DA (1977) Primary adenocarcinoma of the bladder. A retrospective study of 20 patients. J Urol 117:54-56
- Jakse G, Schneider H-M, Jacobi GH (1978) Urachal signetring cell carcinoma, a rare variant of vesical adenocarcinoma: Incidence and pathological criteria. J Urol 120:764-766

- Jones WA, Gibbons RP, Correa RJ Jr, Cummings KB, Mason JT (1980) Primary adenocarcinoma of bladder. Urology 15:119-122
- 12. Leong SA, Jacobo E, Hawtrey CE, Culp DA (1978) Adenocarcinoma of the urachus. J Urol 119:68-71
- Lin R-Y, Rappoport AE, Deppisch LM, Natividad NS, Katz W (1977) Squamous cell carcinoma of the urachus. J Urol 118:1066-1067
- Mekras GD, Block NL, Carrion HM, Ishikoff M (1980) Urachal carcinoma: Diagnosis by computerized axial tomography. J Urol 123:275-277
- Miller A, Mitchell JP, Brown NJ (1969) The Bristol bladder tumor registry. Br J Urol 41:Suppl p 25
- Mostofi FK, Thomson RV, Dean AL (1955) Mucous adenocarcinoma of urinary bladder. Cancer 8:741-758
- Nadji B, Whitehead ED, McKiel CF JR, Graf EC, Callahan DH (1968) Carcinoma of the urachus: Report of two cases and review of the literature. J Urol 100:738-743
- Ohman U, Garrelts B von, Moberg A (1971) Carcinoma of the urachus. Review of literature and report of two cases. Scand J Urol Nephrol 5:91-95
- Pujari BD, Phansopkar M, Deodhare SG (1977) Squamous cell carcinoma of the urachus with vesical calculus. Br J Urol 49:292
- Rubell D, Porges R (1972) Carcinoma of the urachus. A case report-review. Obstet Gynecol 39:753-755
- 21. Thomas DG, Ward AM, William JL (1971) A study of 52 cases of adenocarcinoma of the bladder. Br J Urol 43:4-15
- 22. Wheeler JD, Hill WT (1954) Adenocarcinoma involving the urinary blader. Cancer 7:119-135
- Whitehead ED, Tessler AN (1971) Carcinoma of the urachus. Br J Urol 43:468-476
- Wright HB, McFarlane DJ (1955) Carcinoma of the urachus. Am J Surg 90:693-697
- 25. Yu HHY, Leong CH (1975) Carcinoma of the urachus. Report of one case and review of the literature. Surgery 77:726-729

Mohammad Ghazizadeh, M.D. Department of Urology University of Tokushima Kuramoto-Cho, Tokushima 770 Japan